JP2020524994A5 - - Google Patents

Download PDF

Info

Publication number
JP2020524994A5
JP2020524994A5 JP2019568660A JP2019568660A JP2020524994A5 JP 2020524994 A5 JP2020524994 A5 JP 2020524994A5 JP 2019568660 A JP2019568660 A JP 2019568660A JP 2019568660 A JP2019568660 A JP 2019568660A JP 2020524994 A5 JP2020524994 A5 JP 2020524994A5
Authority
JP
Japan
Prior art keywords
cell
zfns
called
gene
zfn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019568660A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020524994A (ja
JP7419073B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/037844 external-priority patent/WO2018232296A1/en
Publication of JP2020524994A publication Critical patent/JP2020524994A/ja
Publication of JP2020524994A5 publication Critical patent/JP2020524994A5/ja
Priority to JP2022137773A priority Critical patent/JP7482176B2/ja
Application granted granted Critical
Publication of JP7419073B2 publication Critical patent/JP7419073B2/ja
Priority to JP2024017157A priority patent/JP2024036610A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019568660A 2017-06-16 2018-06-15 T細胞および/またはhla受容体の標的化破壊 Active JP7419073B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022137773A JP7482176B2 (ja) 2017-06-16 2022-08-31 T細胞および/またはhla受容体の標的化破壊
JP2024017157A JP2024036610A (ja) 2017-06-16 2024-02-07 T細胞および/またはhla受容体の標的化破壊

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762521132P 2017-06-16 2017-06-16
US62/521,132 2017-06-16
US201762542052P 2017-08-07 2017-08-07
US62/542,052 2017-08-07
US201762573956P 2017-10-18 2017-10-18
US62/573,956 2017-10-18
PCT/US2018/037844 WO2018232296A1 (en) 2017-06-16 2018-06-15 Targeted disruption of t cell and/or hla receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022137773A Division JP7482176B2 (ja) 2017-06-16 2022-08-31 T細胞および/またはhla受容体の標的化破壊

Publications (3)

Publication Number Publication Date
JP2020524994A JP2020524994A (ja) 2020-08-27
JP2020524994A5 true JP2020524994A5 (cg-RX-API-DMAC7.html) 2021-06-17
JP7419073B2 JP7419073B2 (ja) 2024-01-22

Family

ID=64656803

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019568660A Active JP7419073B2 (ja) 2017-06-16 2018-06-15 T細胞および/またはhla受容体の標的化破壊
JP2022137773A Active JP7482176B2 (ja) 2017-06-16 2022-08-31 T細胞および/またはhla受容体の標的化破壊
JP2024017157A Pending JP2024036610A (ja) 2017-06-16 2024-02-07 T細胞および/またはhla受容体の標的化破壊

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022137773A Active JP7482176B2 (ja) 2017-06-16 2022-08-31 T細胞および/またはhla受容体の標的化破壊
JP2024017157A Pending JP2024036610A (ja) 2017-06-16 2024-02-07 T細胞および/またはhla受容体の標的化破壊

Country Status (11)

Country Link
US (1) US20230295563A1 (cg-RX-API-DMAC7.html)
EP (1) EP3638783A4 (cg-RX-API-DMAC7.html)
JP (3) JP7419073B2 (cg-RX-API-DMAC7.html)
KR (1) KR102708624B1 (cg-RX-API-DMAC7.html)
CN (1) CN110997913B (cg-RX-API-DMAC7.html)
AU (1) AU2018283310B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019026622A2 (cg-RX-API-DMAC7.html)
CA (1) CA3066641A1 (cg-RX-API-DMAC7.html)
IL (1) IL271298A (cg-RX-API-DMAC7.html)
SG (1) SG11201911729SA (cg-RX-API-DMAC7.html)
WO (1) WO2018232296A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL268110B2 (en) * 2017-01-26 2024-01-01 Sangamo Therapeutics Inc B-cell engineering
EP4234570A3 (en) * 2018-09-18 2023-12-13 Sangamo Therapeutics, Inc. Programmed cell death 1 (pd1) specific nucleases
EP4237542A1 (en) 2020-10-28 2023-09-06 Sangamo Therapeutics, Inc. Generation of cd4+ effector and regulatory t cells from human pluripotent stem cells
CN113846070B (zh) * 2021-10-18 2023-05-16 翌圣生物科技(上海)股份有限公司 高活性的mTET2酶突变体、其编码DNA及其应用
CN118325904B (zh) * 2024-06-17 2024-10-01 天海元祺生物科技(天津)有限公司 高度靶向人类HLA-A基因的sgRNA、其组合物及应用
WO2026083329A1 (en) 2024-10-18 2026-04-23 Precision Biosciences, Inc. Methods of nuclease-initiated homology directed repair and replacement and compositions and uses thereof
WO2026083328A1 (en) 2024-10-18 2026-04-23 Precision Biosciences, Inc. Base editing nucleotide sequences using homology directed repair

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004235395A1 (en) * 2003-04-29 2004-11-11 Wyeth Methods for prognosis and treatment of solid tumors
WO2009130695A2 (en) * 2008-04-21 2009-10-29 Danziger Innovation Ltd. Plant viral expression vectors and use of same for generating genotypic variations in plant genomes
ES2588730T3 (es) * 2011-03-17 2016-11-04 Miltenyi Biotec Gmbh Preparados celulares agotados en lo que respecta a TCRalfa/beta
WO2012127464A2 (en) * 2011-03-23 2012-09-27 Gavish-Galilee Bio Applications Ltd Constitutively activated t cells for use in adoptive cell therapy
CA2920899C (en) * 2013-08-28 2023-02-28 Sangamo Biosciences, Inc. Compositions for linking dna-binding domains and cleavage domains
RU2752933C2 (ru) * 2014-03-11 2021-08-11 Селлектис Способ создания т-клеток, пригодных для аллогенной трансплантации
CA2947466A1 (en) * 2014-05-01 2015-11-05 University Of Washington In vivo gene engineering with adenoviral vectors
CA2991301A1 (en) * 2015-07-13 2017-01-19 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
US11352631B2 (en) * 2015-12-18 2022-06-07 Sangamo Therapeutics, Inc. Targeted disruption of the T cell receptor
AU2016374253B2 (en) * 2015-12-18 2021-10-21 Sangamo Therapeutics, Inc. Targeted disruption of the MHC cell receptor
JP2020530997A (ja) * 2017-08-08 2020-11-05 サンガモ セラピューティクス, インコーポレイテッド キメラ抗原受容体媒介性細胞標的化
BR112020015488A2 (pt) * 2018-02-08 2020-12-08 Sangamo Therapeutics, Inc. Nucleases alvo-específicas modificadas

Similar Documents

Publication Publication Date Title
Olson Toward the correction of muscular dystrophy by gene editing
JP2017500061A5 (cg-RX-API-DMAC7.html)
JP7396783B2 (ja) 移植を改善するためのcrispr/cas関連方法および組成物
JP2019517803A5 (cg-RX-API-DMAC7.html)
Youngblood et al. Acquired transcriptional programming in functional and exhausted virus-specific CD8 T cells
JP2018532428A5 (cg-RX-API-DMAC7.html)
JP2017504354A5 (cg-RX-API-DMAC7.html)
Linscheid et al. Minor histocompatibility antigens and the maternal immune response to the fetus during pregnancy
JP2021513338A5 (cg-RX-API-DMAC7.html)
JP2016513460A5 (cg-RX-API-DMAC7.html)
NZ743429A (en) Targeted disruption of the mhc cell receptor
JP2025504392A5 (cg-RX-API-DMAC7.html)
JP2022541502A5 (cg-RX-API-DMAC7.html)
JP2024036610A (ja) T細胞および/またはhla受容体の標的化破壊
US20220112280A1 (en) Transplant tolerance induction with carbodiimide treated tolerizing vaccine
FI3169778T3 (fi) Ituradan soluja ablatoiva nanos-geeninpoisto
JP7416745B2 (ja) 改変細胞、調製方法、及び構築物
Sin et al. Transplantation of gene-edited hepatocyte-like cells modestly improves survival of arginase-1-deficient mice
Matsunaga et al. Single-step generation of gene knockout-rescue system in pluripotent stem cells by promoter insertion with CRISPR/Cas9
Beck‐Engeser et al. APOBEC3 enzymes restrict marginal zone B cells
Hoff et al. Recipient HLA-C haplotypes and microRNA 148a/b binding sites have no impact on allogeneic hematopoietic cell transplantation outcomes
JP2019531754A5 (cg-RX-API-DMAC7.html)
JP2025072470A (ja) ホーミングエンドヌクレアーゼバリアント
Keating et al. A robust knock-in approach using a minimal promoter and a minicircle
Aigner et al. Genetically tailored pig models for translational biomedical research